Laiman Xiang

Title: Laiman Xiang: Innovator in Antibody Development

Introduction

Laiman Xiang is a notable inventor based in Fairfax Station, VA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for medical applications. His work focuses on creating innovative solutions for detecting and treating B cell malignancies.

Latest Patents

Laiman Xiang holds a patent for "IRTA2 antibodies and methods of use." This patent discloses antibodies that specifically bind to the extracellular domain of IRTA2. Notably, these antibodies do not bind to IRTA1, IRTA3, IRTA4, or IRTA5. In one embodiment, the antibodies are humanized and can be conjugated to various effector molecules, including detectable labels, radionucleotides, toxins, and chemotherapeutic agents. The antibodies that specifically bind IRTA2 are particularly useful for detecting B cell malignancies, such as hairy cell leukemia and non-Hodgkin's lymphoma. Furthermore, these antibodies can also be employed in the treatment of B cell malignancies that express IRTA2.

Career Highlights

Laiman Xiang is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this prestigious institution has allowed him to contribute to groundbreaking research in the field of immunology and cancer treatment.

Collaborations

Laiman has collaborated with esteemed colleagues, including Ira H Pastan and Tomoko Ise. These collaborations have further enhanced the impact of his research and innovations in the field.

Conclusion

Laiman Xiang's contributions to antibody development represent a significant advancement in the fight against B cell malignancies. His innovative work continues to pave the way for new therapeutic options in oncology.